Spectrophotometric resolution for quantitative analysis of aspirin and rivaroxaban combination therapy in biological fluids using simple and eco-friendly procedure

Table 2 Determination of ASP and ROX in laboratory-prepared mixtures, marketable sample, human plasma and application of standard addition technique

Sample	Method
Sample	DW	RD	1DD
ASP
Laboratory prepared mixtures (n = 5)*	100.12 ± 0.871	99.93 ± 0.854	99.77 ± 1.221
Aspirin protect 100 (BTAB235)	99.21 ± 0.699	99.79 ± 1.042	99.98 ± 1.525
Standard addition of dosage form	98.08 ± 0.943	99.73 ± 1.644	100.82 ± 0.650
Human Plasma^a,**
4 µg/mL	99.49 ± 0.805	100.87 ± 0.515	99.81 ± 1.214
12 µg/mL	99.16 ± 0.953	98.85 ± 1.146	100.44 ± 0.589
Standard addition of plasma^a,**	101. 01 ± 0.484	100.04 ± 1.111	99.42 ± 0.921
ROX
Laboratory prepared mixtures (n = 5)*	99.88 ± 1.077	99.93 ± 0.854	99.77 ± 1.221
Xarelto 10 mg (NDC 50458-580-30)	100.74 ± 0.952	100.50 ± 1.013	100.80 ± 0.437
Standard addition of dosage form	100.67 ± 1.363	99.95 ± 1.040	98.96 ± 0.491
Human Plasma^a**
2 µg/mL	100.24 ± 1.002	99.59 ± 0.892	100.38 ± 0.911
4 µg/mL	100.05 ± 1.071	100.91 ± 0.819	101.06 ± 0.794
Standard addition for plasma^a,**	99.92 ± 1.447	100.12 ± 1.589	100.30 ± 1.033

ISSN: 2661-801X